{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Enhanced Recovery After Surgery Protocols in Total Joint Replacement: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomised controlled trial was conducted at a tertiary care hospital."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults undergoing TJR, with eligibility criteria including age 18-75 and ASA physical status I-III."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received ERAS protocols, while the control group received standard care."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the application of ERAS protocols in total joint replacement (TJR) surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was hospital length of stay (LOS), measured over a 30-day postoperative period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the ERAS group and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis included 98 participants in the ERAS group and 97 in the control group, using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The ERAS group had a significantly reduced LOS (mean difference = 1.5 days, 95% CI 1.0 to 2.0; p < 0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 3% of the ERAS group and 1% of the control group, with mild gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT01234567."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by the National Institutes of Health."
      }
    },
    "total_score": 23,
    "max_score": 25
  },
  "model": "gpt-4o"
}